PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsNivolumab
Opdivo(nivolumab)
Opdivo, Opdualag (nivolumab) is an antibody pharmaceutical. Nivolumab was first approved as Opdivo on 2014-12-22. It is used to treat kidney neoplasms, lymphoma, melanoma, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat colorectal neoplasms, hodgkin disease, melanoma, mesothelioma, and non-small-cell lung carcinoma amongst others. The pharmaceutical is active against programmed cell death protein 1.
Download report
Favorite
Drugs Approved for Childhood Cancers
BMS
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Opdivo
Combinations
Opdualag
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Nivolumab
Tradename
Proper name
Company
Number
Date
Products
OpdivonivolumabBristol Myers SquibbN-125554 RX2014-12-22
4 products
Nivolumab
+
Relatlimab
Tradename
Proper name
Company
Number
Date
Products
Opdualagnivolumab and relatlimab-rmbwBristol Myers SquibbN-761234 RX2022-03-18
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
opdivoBiologic Licensing Application2024-10-03
opdualagBiologic Licensing Application2024-03-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
lymphoma—D008223C85.9
urinary bladder neoplasms—D001749C67
melanoma—D008545—
kidney neoplasmsEFO_0003865D007680C64
squamous cell carcinoma—D002294—
Agency Specific
FDA
EMA
Expiration
Code
nivolumab, Opdivo, Bristol-Myers Squibb Company
2030-02-15Orphan excl.
nivolumab / relatlimab, Opdualag, Bristol-Myers Squibb Company
2029-03-18Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
— L01FF01: Nivolumab
HCPCS
Code
Description
J9299
Injection, nivolumab, 1 mg
Clinical
Clinical Trials
1801 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.013421936141375
MelanomaD008545——12817838347335
NeoplasmsD009369—C802061588216301
Non-small-cell lung carcinomaD002289——10515331444286
Lung neoplasmsD008175HP_0100526C34.907512831431232
Renal cell carcinomaD002292EFO_0000376—689614226176
Liver neoplasmsD008113EFO_1001513C22.03753811190
Kidney neoplasmsD007680EFO_0003865C641021221344
OncogenesD009857——1——1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.951716—2109
Squamous cell carcinomaD002294——315714—14105
AdenocarcinomaD000230——376110—898
Colorectal neoplasmsD015179——47644—796
Squamous cell carcinoma of head and neckD000077195——38499—1496
Hepatocellular carcinomaD006528—C22.037575—1391
RecurrenceD012008——35455—179
Neoplasm metastasisD009362EFO_0009708—38353—569
Stomach neoplasmsD013274EFO_0003897C16233413—865
Hodgkin diseaseD006689—C8123394—255
Show 54 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C253933———60
Triple negative breast neoplasmsD064726——1916———27
GliomaD005910EFO_0000520—1112——119
Large b-cell lymphoma diffuseD016403—C83.31211———19
Hematologic neoplasmsD019337——128———17
Rectal neoplasmsD012004——614———17
Castration-resistant prostatic neoplasmsD064129——99———16
Endometrial neoplasmsD016889EFO_0004230—812———16
Neuroendocrine carcinomaD018278——411———14
Neuroendocrine tumorsD018358EFO_1001901D3A.8113———14
Show 251 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autoimmune diseasesD001327HP_0002960M30-M362———35
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—3————3
ArthritisD001168HP_0001369M05-M142———13
AnemiaD000740HP_0001903D64.92————2
Myeloid leukemia chronic-phaseD015466——2————2
Hematopoietic stem cell transplantationD018380——2————2
Fallopian tube diseasesD005184EFO_0009548N832————2
PsoriasisD011565EFO_0000676L402————2
Ulcerative colitisD003093EFO_0000729K512————2
Rheumatoid arthritisD001172EFO_0000685M06.92————2
Show 41 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyocarditisD009205—I51.4————33
Heart diseasesD006331EFO_0003777I51.9————22
MicrobiotaD064307——————22
MetagenomeD054892——————22
Multiple primary neoplasmsD009378——————22
Cardiovascular diseasesD002318HP_0001626—————11
CardiomyopathiesD009202EFO_0000318I42————11
PericarditisD010493EFO_0007427I30————11
VasculitisD014657HP_0002633—————11
High-throughput nucleotide sequencingD059014——————11
Show 25 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNivolumab
INNnivolumab
Description
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, colon cancer, and liver cancer. It is used by slow injection into a vein.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>5GGQ:H|nivolumab heavy chain QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLF LQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH >5GGQ:L|nivolumab light chain EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEP EDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5GGQ, 5GGR, 5WT9
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108738
ChEBI ID—
PubChem CID—
DrugBankDB09035
UNII ID31YO63LBSN (ChemIDplus, GSRS)
Target
Agency Approved
PDCD1
PDCD1
Organism
Homo sapiens
Gene name
PDCD1
Gene synonyms
PD1
NCBI Gene ID
5133
Protein name
programmed cell death protein 1
Protein synonyms
CD279, programmed cell death 1 protein, protein PD-1, systemic lupus erythematosus susceptibility 2
Uniprot ID
Q8IX89
Mouse ortholog
Pdcd1 (18566)
programmed cell death protein 1 (Q02242)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Opdualag – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Opdivo – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 64,135 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
78,053 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use